menu
    • menu

    Company profile for Sigma-Aldrich Corporation

    Default Key Product, Service and Excipients
    News
    MilliporeSigma Announces a Boost in Commercial Capacity in France

    04 Oct 2022

    // PRESS RELEASE

    Merck Partners with GI Innovation for Biomedicine Development

    11 Nov 2021

    // PRESS RELEASE

    MilliporeSigma’s Danvers Facility Honored as a Manufacturer

    06 Oct 2021

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    BioProcess International

    Booth #319

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Related CompaniesRelated Companies

    About

    Sigma-Aldrich, part of Merck KGaA, Darmstadt, Germany, partners with the global scientific community to tackle the toughest challenges in life science. With over 300,000 products, we offer scientists and engineers top-quality lab materials, technologies, and services to support research and biotech production. Our mission is to simplify processes, enhance efficiency, and ensure safety, helping accelerate access to better health solutions for people everywhere. Through innovation, collaboration, and expertise, we empower discoveries that transform healthcare and improve lives.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sigma-Aldrich CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3050 Spruce St, St. Louis, MO 63103
    Telephone
    Telephone
    Client Email
    Email
    mahirs.patel@merckgroup.com
    Client Website
    Website
    https://www.sigmaaldrich.com/IN/en
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sigma-aldrich/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI WW Frankfurt

    Booth #9.1D64

    envelop Contact Supplier

    CPhI WW Frankfurt

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    NEWS #PharmaBuzz

    read-more
    read-more
    MilliporeSigma Announces a Boost in Commercial Capacity in France
    MilliporeSigma Announces a Boost in Commercial Capacity in France

    04 Oct 2022

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/boost-commercial-capacity-ctdmo-services

    PRESS RELEASE
    04 Oct 2022
    Share Share
    Merck Partners with GI Innovation for Biomedicine Development
    Merck Partners with GI Innovation for Biomedicine Development

    11 Nov 2021

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/p546212077

    PRESS RELEASE
    11 Nov 2021
    Share Share
    MilliporeSigma’s Danvers Facility Honored as a Manufacturer
    MilliporeSigma’s Danvers Facility Honored as a Manufacturer

    06 Oct 2021

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/p403742690

    PRESS RELEASE
    06 Oct 2021
    Share Share
    Merck Licenses Patented CRISPR-Cas9 Tech to Cellecta, Inc.
    Merck Licenses Patented CRISPR-Cas9 Tech to Cellecta, Inc.

    05 Oct 2021

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/p868297324

    PRESS RELEASE
    05 Oct 2021
    Share Share
    Merck Funds IIT Bombay for Covid-19 Research
    Merck Funds IIT Bombay for Covid-19 Research

    26 Aug 2021

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/p352026778

    PRESS RELEASE
    26 Aug 2021
    Share Share
    Merck KGaA’s MA units rank in Boston Globe Top Workplaces
    Merck KGaA’s MA units rank in Boston Globe Top Workplaces

    20 Nov 2020

    // PRESS RELEASE

    https://www.sigmaaldrich.com/IN/en/collections/press/p353808037

    PRESS RELEASE
    20 Nov 2020
    Share Share

    USDMF

    read-more
    read-more

    01

    (r)-dotap Chloride

    Switzerland
    BIOHK2025
    Not Confirmed
    arrow

    02

    Asellacrin (somatropin)

    Germany
    BIOHK2025
    Not Confirmed
    arrow

    03

    Benzyl Alcohol

    U.S.A
    BIOHK2025
    Not Confirmed
    arrow

    04

    Bisoprolol Fumarate 2:1

    Germany
    BIOHK2025
    Not Confirmed
    arrow

    05

    Boric Acid

    Germany
    BIOHK2025
    Not Confirmed
    arrow

    06

    Brompheniramine Maleate

    U.S.A
    BIOHK2025
    Not Confirmed
    arrow

    07

    Bulk Grf (1-29) Nh2 (sermorelin Acet...

    Germany
    BIOHK2025
    Not Confirmed
    arrow

    08

    Calcium Acamprosate New Drug Substan...

    France
    BIOHK2025
    Not Confirmed
    arrow

    09

    Calcium Chloride Dihydrate

    Germany
    BIOHK2025
    Not Confirmed
    arrow

    10

    Calcium Folinate (calcium Leucovorin...

    Switzerland
    BIOHK2025
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck KGaa Swoops to $2b Neurological Disease Pact with Skyhawk

    Details:

    The collaboration will focus on the discovery of novel RNA-targeting small molecules in select neurological indications with high unmet medical need.


    Lead Product(s): Undisclosed,Inapplicable

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Other Small Molecule

    Recipient: Skyhawk Therapeutics

    Deal Size: $2,000.0 million Upfront Cash: Undisclosed

    Deal Type: Collaboration August 18, 2025

    blank

    01

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed,Inapplicable

    Therapeutic Area : Neurology

    Highest Development Status : Discovery Platform

    Recipient : Skyhawk Therapeutics

    Deal Size : $2,000.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Merck KGaa Swoops to $2b Neurological Disease Pact with Skyhawk

    Details : The collaboration will focus on the discovery of novel RNA-targeting small molecules in select neurological indications with high unmet medical need.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    August 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Follitropin Alfa Pen Vs Powder Bioequivalence In Healthy Males

    Details:

    Follitropin Alfa is a Hormone drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hypogonadism.


    Lead Product(s): Follitropin Alfa,Goserelin Acetate

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Hormone

    Recipient: EMD Serono

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 31, 2025

    blank

    02

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Follitropin Alfa,Goserelin Acetate

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Recipient : EMD Serono

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Follitropin Alfa Pen Vs Powder Bioequivalence In Healthy Males

    Details : Follitropin Alfa is a Hormone drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hypogonadism.

    Product Name : Undisclosed

    Product Type : Hormone

    Upfront Cash : Inapplicable

    July 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Anti-EGFR Therapy in Right-sided Advanced Colorectal Cancer with WT RAS & High AREG/EREG

    Details:

    Cetuximab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Colorectal Neoplasms.


    Lead Product(s): Cetuximab,Irinotecan Hydrochloride,Oxaliplatin,Calcium Folinate,Fluorouracil

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody

    Recipient: Gruppo Oncologico del Nord-Ovest

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 31, 2025

    blank

    03

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cetuximab,Irinotecan Hydrochloride,Oxaliplatin,Calcium Folinate,Fluorouracil

    Therapeutic Area : Oncology

    Highest Development Status : Phase IV

    Recipient : Gruppo Oncologico del Nord-Ovest

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Anti-EGFR Therapy in Right-sided Advanced Colorectal Cancer with WT RAS & High AREG/EREG

    Details : Cetuximab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Colorectal Neoplasms.

    Product Name : Undisclosed

    Product Type : Antibody

    Upfront Cash : Inapplicable

    July 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Completes Acquisition of SpringWorks Therapeutics

    Details:

    Through the acquisition, Merck will leverage SpringWorks’ oncology portfolio, including Ogsiveo (Nirogacestat HBr). It is being indicated for adult patients with progressing desmoid tumors.


    Lead Product(s): Nirogacestat Hydrobromide,Inapplicable

    Therapeutic Area: Oncology Brand Name: Ogsiveo

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Recipient: SpringWorks Therapeutics

    Deal Size: $3,900.0 million Upfront Cash: $3,900.0 million

    Deal Type: Acquisition July 01, 2025

    blank

    04

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nirogacestat Hydrobromide,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Recipient : SpringWorks Therapeutics

    Deal Size : $3,900.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Merck Completes Acquisition of SpringWorks Therapeutics

    Details : Through the acquisition, Merck will leverage SpringWorks’ oncology portfolio, including Ogsiveo (Nirogacestat HBr). It is being indicated for adult patients with progressing desmoid tumors.

    Product Name : Ogsiveo

    Product Type : Other Small Molecule

    Upfront Cash : $3,900.0 million

    July 01, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck KGaA in $3.9 Billion Deal to Buy US bIotech Firm SpringWorks

    Details:

    Through the acquisition, Merck will leverage SpringWorks’ oncology portfolio, including Ogsiveo (Nirogacestat HBr). It is being indicated for adult patients with progressing desmoid tumors.


    Lead Product(s): Nirogacestat HBr,Inapplicable

    Therapeutic Area: Oncology Brand Name: Ogsiveo

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Recipient: SpringWorks Therapeutics

    Deal Size: $3,900.0 million Upfront Cash: $3900 million

    Deal Type: Acquisition April 28, 2025

    blank

    05

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nirogacestat HBr,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Recipient : SpringWorks Therapeutics

    Deal Size : $3,900.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Merck KGaA in $3.9 Billion Deal to Buy US bIotech Firm SpringWorks

    Details : Through the acquisition, Merck will leverage SpringWorks’ oncology portfolio, including Ogsiveo (Nirogacestat HBr). It is being indicated for adult patients with progressing desmoid tumors.

    Product Name : Ogsiveo

    Product Type : Other Small Molecule

    Upfront Cash : $3900 million

    April 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib

    Details:

    Under the terms of the Agreement, Merck initially had an exclusive license to commercialize ABSK021 (pimicotinib) for all indications in the Chinese mainland, Hong Kong, Macau.


    Lead Product(s): Pimicotinib,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Recipient: Abbisko Therapeutics

    Deal Size: $605.5 million Upfront Cash: $70.0 million

    Deal Type: Licensing Agreement March 31, 2025

    blank

    06

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pimicotinib,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Recipient : Abbisko Therapeutics

    Deal Size : $605.5 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Merck Exercised the Option for the Global Rights of Abbisko Therapeutics's Pimicotinib

    Details : Under the terms of the Agreement, Merck initially had an exclusive license to commercialize ABSK021 (pimicotinib) for all indications in the Chinese mainland, Hong Kong, Macau.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : $70.0 million

    March 31, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Vaximm Shares VXM01-Avelumab Combo Results in Glioblastoma

    Details:

    VXM01 is an investigational oral anti-VEGFR-2 vaccine, which is being evaluated in combination with avelumab (PD-L1 inhibitor) for treating patients with recurrent glioblastoma.


    Lead Product(s): VXM01,Avelumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Vaccine

    Recipient: Vaximm AG

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 26, 2025

    blank

    07

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VXM01,Avelumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Recipient : Vaximm AG

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Vaximm Shares VXM01-Avelumab Combo Results in Glioblastoma

    Details : VXM01 is an investigational oral anti-VEGFR-2 vaccine, which is being evaluated in combination with avelumab (PD-L1 inhibitor) for treating patients with recurrent glioblastoma.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    March 26, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Anti-CEACAM5 ADC M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02)

    Details:

    Undisclosed


    Lead Product(s): M9140,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Merck Group

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 03, 2025

    blank

    08

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : M9140,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Merck Group

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Anti-CEACAM5 ADC M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02)

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    February 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Mirror Biologics, Merck KGaA Collaborate on Metastatic Colorectal Cancer

    Details:

    The collaboration aims to conduct a Phase II to evaluate the combination of an experimental immunotherapy drug, AlloStim, and an immune checkpoint inhibitor, Bavencio avelumab from Merck.


    Lead Product(s): AlloStim,Avelumab

    Therapeutic Area: Oncology Brand Name: AlloStim

    Study Phase: Phase IIProduct Type: Cell and Gene therapy

    Recipient: Mirror Biologics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration January 08, 2025

    blank

    09

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AlloStim,Avelumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Recipient : Mirror Biologics

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Mirror Biologics, Merck KGaA Collaborate on Metastatic Colorectal Cancer

    Details : The collaboration aims to conduct a Phase II to evaluate the combination of an experimental immunotherapy drug, AlloStim, and an immune checkpoint inhibitor, Bavencio avelumab from Merck.

    Product Name : AlloStim

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    January 08, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

    Details:

    Undisclosed


    Lead Product(s): M9466,Carboplatin

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Other Small Molecule

    Recipient: EMD Serono

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 06, 2024

    blank

    10

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed

    Merck Group

    Germany
    arrow
    ECRM CMO & Packaging
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : M9466,Carboplatin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : EMD Serono

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 52...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 06, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Discover the DDS // excipients from this company

    REF. STANDARDS & IMPURITIES

    Check the ref. standards & impurities from this company

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Sigma-Aldrich Corporation and get a quotation

    Sigma-Aldrich Corporation is a supplier offers 29 products (APIs, Excipients or Intermediates).

    Find a price of CAS 127-17-3 bulk with DMF offered by Sigma-Aldrich Corporation

    Find a price of DL-Ornithine hydrochloride bulk with DMF offered by Sigma-Aldrich Corporation

    Find a price of Acepromazine bulk offered by Sigma-Aldrich Corporation

    Find a price of Adenine bulk offered by Sigma-Aldrich Corporation

    Find a price of Bicisate Dihydrochloride bulk offered by Sigma-Aldrich Corporation

    Find a price of Brompheniramine Maleate bulk offered by Sigma-Aldrich Corporation

    Find a price of Calcipotriol bulk offered by Sigma-Aldrich Corporation

    Find a price of Calcitriol bulk offered by Sigma-Aldrich Corporation

    Find a price of Clomipramine Hydrochloride bulk offered by Sigma-Aldrich Corporation

    Find a price of Copper TetraMIBI Tetrafluoroborate bulk offered by Sigma-Aldrich Corporation

    Find a price of Dimethyl Fumarate bulk offered by Sigma-Aldrich Corporation

    Find a price of Doxylamine Succinate bulk offered by Sigma-Aldrich Corporation

    Find a price of DPPC bulk offered by Sigma-Aldrich Corporation

    Find a price of Eribulin bulk offered by Sigma-Aldrich Corporation

    Find a price of Glatiramer Acetate bulk offered by Sigma-Aldrich Corporation

    Find a price of Glycine bulk offered by Sigma-Aldrich Corporation

    Find a price of Halofuginone bulk offered by Sigma-Aldrich Corporation

    Find a price of Indocyanine Green bulk offered by Sigma-Aldrich Corporation

    Find a price of Inosine bulk offered by Sigma-Aldrich Corporation

    Find a price of Lactobacillus Acidophilus bulk offered by Sigma-Aldrich Corporation

    Find a price of Mebrofenin bulk offered by Sigma-Aldrich Corporation

    Find a price of Mechlorethamine bulk offered by Sigma-Aldrich Corporation

    Find a price of Nortriptyline bulk offered by Sigma-Aldrich Corporation

    Find a price of Paricalcitol bulk offered by Sigma-Aldrich Corporation

    Find a price of Promethazine Hydrochloride bulk offered by Sigma-Aldrich Corporation

    Find a price of Sodium Benzoate bulk offered by Sigma-Aldrich Corporation

    Find a price of Sotorasib bulk offered by Sigma-Aldrich Corporation

    Find a price of Tripalmitin bulk offered by Sigma-Aldrich Corporation

    Find a price of Urea C13 bulk offered by Sigma-Aldrich Corporation

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search